Aventis Files Fresh Patent Suit Against Mylan Over Generic Allegra

Law360, New York (September 6, 2005, 12:00 AM EDT) -- Aventis' patents for the lucrative allergy drug Allegra spawned new litigation last week against Mylan Pharmaceuticals, just as new plans were announced by rivals Barr and Teva to cooperate in manufacturing a generic version of some dosages.

France-based Aventis Pharmaceuticals Inc., which in 1996 launched the drug that generated about $1.4 billion in the past year, is once again taking action to protect six patents for certain dosages of Allegra and Allegra-D against West Virginia-based Mylan.

The complaint, filed in U.S. District Court for the District...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.